Introduction: To improve the outcome of patients with cervical cancer, a more accurate prognostic assessment is essential. The aim of this study was to evaluate the role of tumor DNA ploidy as an independent prognostic factor in cervical carcinoma. Furthermore, we investigated whether the presence of lymph node metastasis may have a different clinical impact according to ploidy status. Methods: In a long-term prospective study, DNA ploidy was evaluated by flow cytometry from fresh tumor samples from 136 patients with cervical cancer who underwent surgery. Ploidy, lymph node metastasis, and other classical parameters were analyzed in relation to the length of disease-specific survival. Treatment modalities did not differ between patients with diploid tumors and patients with aneuploid tumors. Results: DNA aneuploidy was found in 52 patients (38.2%). Patients with DNA-aneuploid tumors had a significantly reduced disease-specific survival (P = 0.003). Overall, the 10-year survival probability was 54% for patients with DNA-aneuploid tumors and 80% for patients with DNA-diploid tumors. Among 64 patients with International Federation of Gynecologists and Obstetricians stage I disease, the 10-year survival rates were 38.7% for the patients with DNA-aneuploid tumors and 86.3% for those with DNA-diploid tumors (P = 0.003). Overall, diploid tumors with lymph node metastasis did significantly better than aneuploid tumors with lymph node metastasis (P = 0.05). Among the patients with International Federation of Gynecologists and Obstetricians stage I disease, there was a highly significant difference between patients with diploid nodeYpositive tumors and patients with aneuploid nodeYpositive tumors, with no deaths from the disease in the former group in contrast with the worst outcome in the latter group (P = 0.005). By multivariate analysis, pathologic tumor stage, lymph vascular invasion, and tumor ploidy were significant and independent parameters, whereas lymph node metastasis yielded no independent information. Conclusions: DNA ploidy was an independent prognostic factor in cervical carcinoma. Presence of lymph node metastasis may not always have the same impact on survival but may vary according to DNA ploidy of the primary tumor.
W ith nearly 500,000 new cases per year, cervical cancer is the second most common cancer in women worldwide, although its incidence is constantly decreasing. The long-term decline of cervical carcinoma mortality over the last decade in European countries, with a fall of 19%, is mainly due to a wider adoption of screening programs in western and northern Europe. Prognosis of these patients is influenced by many clinical and pathological features, but the clinical International Federation of Obstetrics and Gynecology (FIGO) stage of disease at diagnosis remains the most important parameter. Currently, pathological features such as histologic type and grade of differentiation, microscopic diffusion to the parametria, and presence of lymph node metastasis are used to predict the course of the disease and to choose the appropriate adjuvant therapy. However, to improve the prognosis of patients with cervical carcinoma, a new, more accurate prognostic assessment is required to identify patients with high-risk disease and to individualize the treatment based on tumor-specific features. Over the last decade, the progressive expansion of knowledge about biomolecular tumor parameters opened new perspectives in the prognostic characterization of this disease. The study of biologic prognostic markers may allow the identification of patients at high risk for relapse and possibly contribute to increase their chance of cure through a better selection of cases that deserve additional therapies. Among the parameters that investigate the biological aggressiveness of the neoplasia, tumor ploidy, DNA index, and synthesis (S)-phase fraction (SPF), as evaluated by flow cytometry, have shown to provide strong prognostic information in several human tumor and in cervical carcinoma as well. 1Y3 The main advantage of these parameters, in comparison with the standard pathologic features, is the possibility of obtaining objective and reproducible information peculiar for each patient. In the literature, there are a number of studies evaluating flow cytometry in carcinoma of the uterine cervix, 2Y16 but results are contradictory. Some studies showed that tumor ploidy, DNA index, and SPF, obtained by flow cytometry, are strong and independent prognostic parameters in comparison with standard pathologic factors. 3, 4, 6, 8, 10, 14 Other studies did not confirm these results. 2,5,7,9,11Y13,15,16 These conflicting evidences hampered a wider diffusion of DNA ploidy determination as standard practice in cervical carcinoma. However, most of the published series are retrospective and based on paraffin-embedded material analysis.
The aim of the present study was to evaluate in a prospective series with long-term follow-up the prognostic significance of tumor ploidy, DNA index, and SPF obtained by flow cytometric analyses of fresh tumor samples from patients with cervical carcinoma who underwent surgical treatment. In addition, we wanted to investigate whether the presence of lymph node metastasis is always associated with a poor outcome or biological aggressiveness of the tumor may influence the meaning of this well-known ominous sign.
MATERIALS AND METHODS

Patients
From June 1993 to March 2000, a total of 345 patients with a diagnosis of FIGO stage IA through stage IVB cervical cancer were seen at our department. In 136 patients undergoing surgery, it was possible to obtain a fresh tumor sample, and they were enrolled in this prospective study. Inclusion in the study was based only on the availability of the researchers involved in taking and processing the samples and in no way was it related to clinical characteristics of the patients. The patients signed an informed consent, and the study was approved by the institutional review board.
The treatment varied according to stage: patients with early-stage disease underwent primary surgery, with 83 radical abdominal hysterectomy (Wertheim-Meigs) and 40 radical vaginal hysterectomy (Schauta-Amreich); pelvic and/or aortic lymphadenectomy was performed in all the patients operated on through the abdominal approach and in selected patients operated on vaginally, using an extraperitoneal technique. 17 Overall, lymphadenectomy was done in 113 patients (83.1%). In selected patients with very early disease (stage IA) or in patients with advanced disease (stage III) who received preoperative radiotherapy, the surgical procedure was limited to total hysterectomy with bilateral salpingo-oophorectomy, which was performed abdominally or vaginally in 8 and 5 patients, respectively. All surgical procedures were performed by the same surgical team. Adjuvant radiotherapy or chemotherapy was given in 52 and 6 patients, respectively, according to the presence of risk factors for recurrence (lymph node metastasis, microscopic involvement of the parametria, and large tumor volume). Most patients with locally advanced disease (stages IIYIII) received preoperative irradiation (14 patients) and/or neoadjuvant chemotherapy (17 patients). In this subgroup of patients with preoperative treatment, a tumor sample for flow cytometry was obtained before the start of any treatment during colposcopy. Ploidy status was not known before treatment and in the whole series, treatment decisions were taken without knowledge of ploidy information.
Follow-Up and Evaluation of Results
After treatment, the patients underwent follow-up visits and a Papanicolaou test every 3 months for 2 years, then every 6 months until the fifth year, and then once a year. Any relapse of the tumor either in the pelvis or distant was notified. Disease-free interval was considered from the date of surgery. Median duration of follow-up was 97.5 months (range, 14Y153 months).
Disease-free interval and cervical cancer-specific survival were the end points of the study.
Flow Cytometric Analysis
The fresh tumor specimens obtained at colposcopy in 31 patients with preoperative treatment and after surgery by means of frozen section in the remaining 105 patients were immediately sent to the laboratory where a suspension of tumor cells was obtained, fixed, and processed or frozen and stored at j80-C until assayed. For flow cytometry, the nuclei were stained with propidium iodide. Human female lymphocytes were added to the sample before enzymatic treatment and staining, and they were used as the DNA diploid standard. Analysis was performed using a FACStar flow cytometer (Becton Dickinson) with a 5-W argon laser fluorescence at 488 nm. The DNA ploidy was given by the DNA index, defined as a proportion of the modal DNA values of the tumor G 0 and G 1 cells (peak channel) to the diploid standard G 0 and G 1 cells. The histograms were based in most instances on more than 100,000 cells and in all cases on more than 10,000 cells and resulted, in general, in a good resolution with a coefficient of variation of 3% to 6%. Calculation of the DNA index and SPF was done using the software Multicycle Autofit Version 2.00 (Phoenix Flow Systems, San Diego, Calif). All cases with a DNA index value of 1 T 0.04 were classified as diploid and others as aneuploid.
Statistical Analysis
The distribution of clinical and pathologic characteristics of the study group by ploidy status was evaluated by the Fisher exact test or by the W 2 test, as appropriate. Diseasespecific survival curves were generated according to the Kaplan-Meier method and evaluated by the log-rank test. Univariate and multivariate analyses (Cox proportional hazard with forward selection of variables) were performed to estimate which of the prognostic factors yielded independent information. Data analysis was performed with the SPSS statistical package, release 12.0 (SPSS Inc, Chicago, Ill). A level of 5% (P e 0.05) was considered statistically significant. All tests were 2 tailed.
RESULTS
Flow Cytometry
Flow cytometric analysis showed a diploid tumor in 84 cases (61.7%) and an aneuploid tumor in 52 cases (38.2%). The DNA index resulted in 1.5 or less in 109 patients (80.2%) and greater than 1.5 in 27 (19.8%). The fraction of cells with S-phase DNA content was evaluable in 133 patients (97.8%); an SPF exceeding that of the median of the samples (98.0%) was considered the cutoff value for the evaluation of the high versus low SPF. In 66 patients (49.6%), there was a high SPF, whereas in the remaining 67 cases (50.4%), SPF was low. DNA index distribution (diploid vs. aneuploid) according to classic clinical-pathologic features is presented in detail in Table 1 . 
Association of Ploidy and SPF With Clinical Outcome
Among the 136 patients in the study, during the followup, there were 50 recurrences and 41 who died of the disease. Tumor ploidy, DNA index, and SPF were significantly correlated with disease-free interval and disease-specific survival by univariate Cox analysis (Table 2) .
Patients with DNA-aneuploid tumors had a significantly reduced disease-specific survival. The 10-year survival probability was 54% for the patients with DNA-aneuploid tumors in contrast to 80% for the patients with DNA-diploid tumors, irrespective of FIGO stage (P = 0.003, log-rank test; Fig. 1A ).
In addition, considering only the patients with stage I disease, tumor ploidy was a significant prognostic factor. In fact, among 64 patients with FIGO stage I disease, the 10-year survival rates were 86.3% for the patients with DNA-diploid tumors and 38.7% for the patients with DNA-aneuploid tumors (P = 0.003, log-rank test; Fig. 1B ). Treatment modalities did not differ according to ploidy status. In particular, in the whole series, adjuvant radiotherapy was given in 28 of 84 diploid and in 24 of 52 aneuploid cases (P = 0.15, Fisher exact test); in the patients with stage I disease, the correspondent figures were 19 of 40 and 10 of 24, respectively (P = 0.79; Fisher exact test). Similarly, on the whole series, cases with a DNA index of 1.5 or less showed a 10-year survival of 72.1% versus 34.5% for cases with a DNA index of greater than 1.5 (P G 0.001, log-rank test), and limiting the analysis to FIGO stage I cases, the survival estimates were 82.4% and 25.0%, respectively (P G 0.001, log-rank test). Considering the percentage of cells with S-phase fraction DNA content, the patients with low SPF did significantly better than the patients with high SPF, with 10-year survival in the whole series of 81.0% and 49.9%, respectively (P G 0.001, log-rank test) and among the patients with FIGO stage I disease of 86.7% and 53.2%, respectively (P = 0.01, log-rank test).
According to univariate Cox analysis, several wellknown pathological parameters such as FIGO stage, presence of parametrial invasion, lymph-vascular spaces infiltration, and lymph node metastasis were also confirmed as significant prognostic factors (Table 2 ). In particular, lymph node metastasis were found in 30 of the 113 patients (26.5%) who underwent lymphadenectomy. Incidence of death of disease was more than 2 folds higher in the group with lymph node metastasis (13/30 [43.3%]) in comparison with that in patients with negative lymph nodes (17/83 [20.4%]) (P = 0.02; Fisher exact test). Considering 10-year survival rates, the patients without lymph node metastasis did significantly better than the patients with positive lymph nodes (75.4% vs 57.2%; P = 0.008, log rank test). However, by stratifying the patients by lymph node status and DNA ploidy, a more accurate definition of the risk of death was possible. Figure 2A presents Kaplan-Meier survival estimates according to these stratified risk groups. With regard to the probability of survival, there was no significant difference between the patients with lymph node metastasis and those without lymph node metastasis if the tumor was diploid (P = 0.25). However, there were statistically significant differences in the probability of survival among other groups of tumors. In particular, diploid tumors with lymph node metastasis did significantly better than aneuploid tumors with lymph node metastasis (P = 0.05) and did even better than aneuploid tumors without lymph node metastasis, although the difference was not statistically significant. By limiting the analysis to patients with FIGO stage I disease, there was no significant difference between the outcome of patients with lymph node metastasis and that of patients without lymph node metastasis when the tumor was DNA diploid. In this specific subgroup of patients, those with DNA diploid and lymph node metastasis did even better than those with DNA diploid without lymph node metastasis. In addition, there was a highly significant difference between the patients with diploid nodeYpositive tumors and those with aneuploid nodeY positive tumors, with no deaths from the disease in the former group in contrast with the worst outcome in the latter group (P = 0.005; Fig. 2B ). Concerning the number of positive lymph nodes, this ranged from 1 to 9. To assess whether a different proportion of patients with multiple metastatic nodes may have influenced the clinical outcome according to ploidy and lymph node status, we compared the distribution of patients with one positive lymph node and 2 or more positive lymph nodes according to DNA ploidy status. The correspondent figures were 8 and 8 versus 6 and 8 for diploid and aneuploid tumors, respectively (difference not significant, Fisher exact test). The relative prognostic significance of lymph node metastasis was confirmed also by multivariate analysis that showed pathologic stage, lymph vascular invasion, and tumor ploidy as significant and independent parameters, whereas well-known prognostic indicators as FIGO stage, lymph node metastasis, FIGURE 2. A, Ten-year probability of survival in 113 patients with cervical cancer as stratified by lymph node status and DNA ploidy. Difference by log-rank test for each group was as follows: diploid-negative versus diploid-positive nodes, P not significant; diploid-negative versus aneuploid-negative nodes, P = 0.03; diploid-negative versus aneuploid-positive nodes, P G 0.001; diploid-positive versus aneuploid-negative nodes, P not significant; diploid-positive versus aneuploid-positive nodes, P = 0.05; aneuploid-negative versus aneuploid-positive nodes, P = 0.02. B, Ten-year probability of survival in 64 FIGO stage I patients as stratified by lymph node status and DNA ploidy. Difference by log-rank test for each group was as follows: diploid-negative versus diploid-positive nodes, P not significant; diploid-negative versus aneuploid-negative nodes, P not significant; diploid-negative versus aneuploid-positive nodes, P G 0.001; diploid-positive versus aneuploid-negative nodes, P = 0.05; diploid-positive versus aneuploid-positive nodes, P = 0.005; aneuploid-negative versus aneuploid-positive nodes, P = 0.02. and Broders grade yielded no significant and independent information. Table 3 shows the results of multivariate analysis.
DISCUSSION
In this prospective study with long-term follow up, we found that DNA ploidy, DNA index, and SPF were significant prognostic factors in cervical carcinoma. The prognostic value of these parameters was confirmed in the overall series and among the patients with FIGO stage I disease.
The prognostic significance of DNA ploidy, DNA index, and SPF in cervical cancer is not new, and several authors previously reported results in agreement with our findings. 3, 4, 6, 8, 10, 14 The strength of our prospective study is that this is the first that presents 10-year results of flow cytometric DNA analysis from fresh tumor samples. In fact, it is known that histograms from paraffin-embedded material are less accurate than those from fresh tissue. 18 Other studies that evaluated fresh tumor samples without evidence of prognostic significance of ploidy level and SPF had a shorter followup 2,5,11Y13,16 and sometimes were also based on the analysis of a smaller series. 5, 9, 13, 16 Observing the trends of the long-term survival curves in the current study, it emerges that among the patients with diploid tumors, most of the death events are concentrated in the first 24 months of follow-up, whereas among the patients with aneuploid tumors, deaths are more frequent in early years but may occur also later in the follow-up. This seems to indicate a different clinical behavior for aneuploid tumors, in agreement with the known biological aggressiveness associated with DNA ploidy abnormalities, with a greater potential not only for quick disease progression but also for late recurrences. 1, 2 This trend of early and late mortality for aneuploid tumors may also account, at least in part, for the difference between our study and those of some authors that did not verify a prognostic role of DNA ploidy in studies with shorter follow-up. 2,5,11Y13,16 Another very interesting outcome of this study was that evaluation of DNA ploidy allowed distinguishing patients with significantly different outcome in relation to a prognostic parameter considered fundamental in cervical cancer worldwide, such as presence of lymph node metastasis. Our study revealed, to the best of our knowledge for the first time, that to have lymph node metastasis is not necessarily a marker of unfavorable outcome in cervical cancer if the tumor is DNA diploid. Indeed, both in the overall series and in limiting the analysis to cases with FIGO stage I disease, patients with positive nodes and diploid tumor fared equally to those without lymph node metastasis and diploid tumor. In other words, the presence of lymph node metastasis does not affect survival if the tumor is DNA diploid. At the same time, those with lymph node metastasis and diploid tumor fared significantly better than those with lymph node metastasis and aneuploid tumor (Figs. 2A, B) . At least in the patients with stage I disease, the patients with lymph node metastasis and diploid tumor had a significantly even better outcome than the patients without lymph node metastasis but with aneuploid tumor (Fig. 2B) . Obviously, our results must be considered with caution, as they are based on a relatively small number of patients with lymph node metastasis. Nonetheless, this quite unexpected finding may suggest that we probably have to reconsider the biological meaning of lymph node metastasis in cervical carcinoma. So far, the surgical efforts of every gynecologic oncologist were oriented toward proper radicality on the parametria and thorough clearance of pelvic nodes to completely eradicate tumor cells and increase cure rate. These goals remain obviously prominent. However, our study seems to point out that the same pathological feature (eg, presence of metastasis to the pelvic lymph nodes) may not have the same clinical implications according to tumor DNA ploidy. This finding is in contrast with a previous study that, using paraffin-embedded samples, failed to identify a prognostic disadvantage for aneuploid tumors, both overall and among patients with nodepositive disease. 7 In the literature, we found a large agreement about the prognostic value of ploidy and SPF concerning ovarian and endometrial cancer. 1 Results about the prognostic significance of ploidy in cervical cancer, instead, are contradictory. Some authors support the independent effect that DNA ploidy plays on survival: Jakobsen 3 in 1984 reported high frequency of lymph node metastasis and relapses in early stage aneuploid cervical carcinomas and this data was independent of radiant or surgical treatment. In another study, 4 the same author described a significantly higher frequency of relapses in stage IB to stage III cervical tumor with DNA index greater than 1.5 in comparison with a DNA index of less than 1.5 cases. Sǿrensen et al 8 in 1992 published a retrospective analysis on 51 patients with stage I to stage III squamous cell carcinomas of the uterine cervix showing that the DNA index resulted in an independent prognostic factor. It also showed that combining DNA index with other variables, such as age or stage, made it possible to identify 2 groups of patients: the low-risk group containing diploid tumors showed a favorable prognosis with a 10-year survival of 92%, whereas the high-risk group with aneuploid tumors presented a poor outcome, with a 10-year survival of 14%. Instead, in other studies, 2, 9, 11, 12, 15, 16 the DNA index was not a significant prognostic factor in patients with cervical cancer. The reasons for this discrepancy are not clear. However, several technical variables may account for these conflicting evidences, including the following: tissue samples (fresh vs paraffin embedded); choice and preparation of 4, 12, 16 Notwithstanding the limitation that methodological differences may introduce in the evaluation of flow cytometric parameters, our long-standing experience with this technique supports the role of DNA ploidy as a prognostic factor in endometrial cancer, 19, 20 and the current study confirms that DNA ploidy is an independent prognostic factor also in cervical carcinoma. In addition, the present study seems to indicate that the biological aggressiveness of the disease associated with different ploidy patterns may influence the clinical significance of lymph node metastasis. In other words, the presence of metastatic disease in the pelvic lymph nodes may not be invariably associated with poor outcome if the tumor is DNA diploid. This result, if confirmed in a larger series, may contribute to a better individualization of treatment. There is no question that the stage of disease remains the main predictor of patients' outcome, as confirmed also by this study. However, implementation of classical pathologic prognostic parameters with more precise biological predictors, such as tumor DNA ploidy, may be helpful in clinical practice. Patients with aneuploid tumors could benefit from more aggressive therapies, whereas patients with diploid disease may receive less intensive treatments. This individually designed approach should result in optimization of patients' chance of cure while minimizing treatment toxicity. In conclusion, our prospective study with long-term results on the prognostic role of flow cytometric DNA ploidy in cervical carcinoma supports continued use of this technique. Further studies are needed to clarify the issue of different clinical meanings of pelvic lymph node metastasis according to tumor DNA ploidy.
